what is tirzepatide glp 1 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly GLP-1 Genetics: How Genes Affect

Related Research Comparisons The landscape of obesity treatment continues to evolve with multiple investigational compounds targeting different pathways

Tirzepatide works by slowing gastric emptying and signaling fullness through dual GLP-1 and GIP pathways, suppressing appetite in ways that take time to reverse

Protocol Specifications: Daily Dose: 20-30 mcg Frequency: Once daily Best Timing: Post-workout OR before bed Injection Method: Subcutaneous (abdomen or thighs) Cycle Length: 4 weeks total Progressive Dosing Schedule: Week 1-2: 20 mcg/day (establish baseline tolerance) Week 3-4: 25-30 mcg/day (if no adverse effects observed) Expected Timeline: Most beginners notice improved recovery from workouts within 3-5 days as IGF-1 LR3 reduces muscle damage and accelerates repair

No Canadian province lists Wegovy on its standard drug formulary as of 2026